Abstract: Peptide receptor radionuclide therapy (PRRT) is a successful targeted method for patients with neuroendocrine tumor (NET) who cannot be operated on, with no response to systemic therapy, but with somatostatin receptor overexpression confirmed by nuclear medical imaging. It can prolong survival and improve symptom control and quality of life in these patients. However, the patients with complete response are few, and there are still more patients with disease progression. So, some new approaches, including combination therapy with PRRT and α-nuclide-based PRRT, have attracted much attention recently. Here, this article reviews the research progress of the new PRRT strategies based on both domestic and foreign studies in this field.